Ghamande SS, Klaassen Z, Wallis CJD. Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. Eur Urol 2023 May 12:S0302-2838(23)02794-X. doi: 10.1016/j.eururo.2023.
PMID: 37183160